Posts by Follicle Thought
Kintor Releases Phase 2 Trial Results for GT20029
Kintor Pharmaceuticals has announced that its proteolysis targeting chimera (PROTAC) drug GT20029 has reached its primary endpoint in its Phase 2 trial in China. GT20029 is a topical PROTAC targeted toward AGA. What are PROTACs? PROTACs are a novel class of heterobifunctional molecules that can induce the degradation of target proteins by hijacking the cell’s…
Read MoreInterview with CEO of Stemson Therapeutics, Geoff Hamilton – Updates and the Future
Follicle Thought is pleased to present a recent interview we conducted with Geoff Hamilton, the CEO of Stemson Therapeutics. Stemson Therapeutics is a biotech company founded in 2018 that aims to revolutionize hair regrowth through stem cell technology. So, let’s get into the interview. FT: Hi Geoff, Thank you for coming back to Follicle Thought…
Read MoreNektar Therapeutics Launches a Phase 2b Trial for Alopecia Areata
This week, there is interesting news for those with alopecia areata. Nektar Therapeutics has announced that it will launch a Phase 2b trial for its drug rezpegaldesleukin (REZPEG), which will be assessed in individuals suffering from severe to very severe alopecia areata (AA). Nektar Therapeutics is a biotech firm with several indications in the pipeline…
Read MorePelage Pharma Gains New Injection of Funds to Progress into Phase 2
Positive news for Pelage Pharma as they close their Series A funding round. Pelage Pharma is a regenerative medicine company developing a topical treatment called PP405 that is claimed to reactivate dormant hair follicle stem cells and trigger new hair growth. This treatment is aimed at people suffering from all types of hair loss. Pelage…
Read MoreStemson Therapeutics – iPSCs for Hair Regeneration
Earlier this month, Stemson Therapeutics announced its hair follicle regeneration research advancement. What is Stemson Therapeutics Working On? The company is focused on developing a cell therapy solution for hair loss. They use autologous (meaning from the self) induced pluripotent stem cells (iPSCs) to engineer follicular units to form new hair follicles. These will be…
Read MoreInterview: Xunwei Wu – Hair Regeneration Research
We interviewed skin and hair biology researcher Xunwei Wu about his ongoing research in hair follicle regeneration. Let’s look at what researchers are working on for the future of hair regrowth. Who is Xunwei Wu? Xunwei Wu is a researcher who has worked in dermatology (specifically skin biology) for more than 20 years. In the…
Read MoreOG6: A New Research Avenue for Hair Growth?
A team of researchers led by Chunming Wang from the University of Macau, in collaboration with scientists from the University of Nanjing and Wenzhou Medical University, have conducted a study on the use of an oligosaccharide biomaterial (OG6) to stimulate hair growth in mice. The study is based on understanding the crucial role of local…
Read MoreTechnoderma Medicines Inc. Successfully Completes Phase 2a Clinical Trial
Interesting news from Technoderma Medicines Inc. about their Phase 2a trial. TDM-105795: Positive Results Observed Compared to Baseline Technoderma Medicines Inc. has completed a Phase 2a clinical trial for TDM-105795, “A Randomized, Double-Blind, Vehicle Controlled, Parallel Group, Multi-Dose Study to Evaluate the Efficacy and Safety of TDM-105795 in Male Subjects with Androgenetic Alopecia.” TDM-105795 is…
Read MoreAesthetic Tech Forum 2024: Advancements in Hair Restoration
The Aesthetic Tech Forum 2024 is underway (January 25th and 26th) and features a session titled “Revitalizing Radiance: Advances in Hair Restoration“. Panelists include: Wajdie Ahmad, Executive Chairman & COO of Amplifica Holdings Group, Inc.; Amplifica is a biopharmaceutical company with several treatments in the pipeline targeted towards androgenic alopecia (AMP-303, AMP-203, and AMP-601). Drew…
Read MoreHope Medicine Announces Phase 1b Results for HMI-115
Positive news to start the new year with Hope Medicine’s HMI-115 Phase 1b results announced on January 14th, 2024. Successful Results for Male Participants Hope Medicine has released positive data from their Phase 1b trial conducted in Australia titled, “An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia…
Read More